These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29430731)

  • 1. Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
    Goepel L; Jacobi A; Augustin M; Radtke MA
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e311-e313. PubMed ID: 29430731
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.
    Kocoglu H; Karaca M; Turkay R; Tural D
    J BUON; 2016; 21(3):754-5. PubMed ID: 27569104
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
    Hirsch FR; Bunn PA
    Nat Rev Clin Oncol; 2015 Dec; 12(12):689-90. PubMed ID: 26552954
    [No Abstract]   [Full Text] [Related]  

  • 4. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
    Womack JP; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2015 Dec; 10(12):e115-8. PubMed ID: 26709484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.
    Novello S
    J Clin Oncol; 2015 Dec; 33(34):3985-6. PubMed ID: 26438112
    [No Abstract]   [Full Text] [Related]  

  • 6. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer].
    Cheng F; Wang J; Chen J; Xing P; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):679-681. PubMed ID: 27760598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study.
    Pezzuto A; Stumbo L; Russano M; Crucitti P; Scarlata S; Caricato M; Tonini G
    Recent Pat Anticancer Drug Discov; 2015; 10(3):342-51. PubMed ID: 26246248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
    Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[
    Abdulla DSY; Scheffler M; Brandes V; Ruge M; Kunze S; Merkelbach-Bruse S; Nogova L; Michels S; Fischer R; Riedel R; Büttner R; Persigehl T; Grau S; Galldiks N; Drzezga A; Kobe C; Wolf J
    Clin Lung Cancer; 2019 Mar; 20(2):e148-e151. PubMed ID: 30528316
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug companies settle claim of misleading doctors on cancer survival data.
    Dyer O
    BMJ; 2016 Jun; 353():i3361. PubMed ID: 27307418
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
    Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
    Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
    Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.